Systemic lupus erythematosus (SLE) is an autoimmune disorder of largely unknown etiology characterized by profound effector T cell dysfunction. Infection-related morbidity and mortality rates are high among patients with SLE and although multifactorial it has been attributed to disease activity, the use of immunosuppressive drugs and deficient cell-mediated cytotoxic responses that are associated with decreased expression of interleukin (IL)-2. IL-17 production on the other hand is increased in SLE patients and mice and IL17-producing cells invade the kidney in patients with lupus nephritis. cAMP response element modulator (CREM)? has been claimed to suppress the production of IL-2 through transcriptional and epigenetic mechanisms and to promote the production of IL-17 through epigenetic modulation. It is postulated herein that CREM? effects transcriptional and epigenetic modifications which account for the antithetic expression of IL2 and IL-17 and the subsequent disease expression in patients with SLE and lupus- prone mice and that silencing it should have a clinical benefit. Accordingly, experiments are proposed to understand the CREM? -mediated transcriptional and epigenetic mechanisms that are involved in the control of expression of IL-2 and IL-17 in SLE and the distribution of IL-17-producing cells in tissues, to establish the role of CREM? in the regulation of autoimmunity and lupus-related pathology in mice and to treat lupus-prone mice with an inducible IL-2 gene expression system and by silencing CREM?. The proposed work using novel concepts (epigenetic control of cytokine production) and novel, genetically modified, mice intends to clarify central mechanisms in the pathogenesis of SLE and to introduce infusion of IL-2 or silencing of CREM as new treatments for SLE.
Systemic lupus erythematosus (SLE) is an autoimmune disorder of largely unknown etiology in which infection and lupus nephritis -related morbidity and mortality rates are high. Deregulated interleukin-2 and -17 production accounts for disease expression. The proposal will produce information which will explain why cytokine production is aberrant in SLE and through preclinical studies will recommend novel treatment approaches.
|Moulton, Vaishali R; Suarez-Fueyo, Abel; Meidan, Esra et al. (2017) Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med 23:615-635|
|Comte, Denis; Karampetsou, Maria P; Yoshida, Nobuya et al. (2017) Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis Rheumatol 69:1035-1044|
|Geha, Mayya; Tsokos, Maria G; Bosse, Robin E et al. (2017) IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury. J Immunol 199:2921-2929|
|Comte, Denis; Karampetsou, Maria P; Kis-Toth, Katalin et al. (2017) Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2. Arthritis Rheumatol 69:808-813|
|Comte, Denis; Karampetsou, Maria P; Kis-Toth, Katalin et al. (2016) Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci U S A 113:9321-6|
|Yoshida, Nobuya; Comte, Denis; Mizui, Masayuki et al. (2016) ICER is requisite for Th17 differentiation. Nat Commun 7:12993|
|Moulton, Vaishali R; Tsokos, George C (2015) T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest 125:2220-7|
|Lieberman, Linda A; Tsokos, George C (2014) Lupus-prone mice fail to raise antigen-specific T cell responses to intracellular infection. PLoS One 9:e111382|
|Grammatikos, Alexandros P; Kyttaris, Vasileios C; Kis-Toth, Katalin et al. (2014) A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin Immunol 150:192-200|
|Hedrich, Christian M; Crispín, José C; Rauen, Thomas et al. (2014) cAMP responsive element modulator (CREM) ? mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells. J Biol Chem 289:2361-70|
Showing the most recent 10 out of 17 publications